Chidamide and sintilimab combination in diffuse large B-cell lymphoma progressing after chimeric antigen receptor T therapy  

作　　者：Yuan-Yuan Hao Pan-Pan Chen Xiang-Gui Yuan Ai-Qi Zhao Yun Liang Hui Liu Wen-Bin Qian 

机构地区：[1]Department of Hematology,The Second Affiliated Hospital of Zhejiang University School of Medicine,Hangzhou 310009,Zhejiang Province,China

出　　处：《World Journal of Clinical Cases》2022年第19期6555-6562,共8页世界临床病例杂志

摘　　要：BACKGROUND Diffuse large B-cell lymphoma(DLBCL)is curable with first-line chemoimmunotherapy but patients with relapsed/refractory(R/R)DLBCL still face a poor prognosis.For patients with R/R DLBCL,the complete response rate to traditional next-line therapy is only 7%and the median overall survival is 6.3 mo.Recently,CD19-targeting chimeric antigen receptor T cells(CAR-T)have shown promise in clinical trials.However,approximately 50%of patients treated with CAR-T cells ultimately progress and few salvage therapies are effective.CASE SUMMARY Here,we report on 7 patients with R/R DLBCL whose disease progressed after CAR-T infusion.They received a PD-1 inhibitor(sintilimab)and a histone deacetylase inhibitor(chidamide).Five of the 7 patients tolerated the treatment without any serious adverse events.Two patients discontinued the treatment due to lung infection and rash.At the 20-mo follow-up,the median overall survival of these 7 patients was 6 mo.Of note,there were 2 complete response rates(CRs)and 2 partial response rates(PRs)during this novel therapy,with an overall response rate(ORR)of 57.1%,and one patient had a durable CR that lasted at least 20 mo.CONCLUSION In conclusion,chidamide combined with sintilimab may be a choice for DLBCL patients progressing after CD19-targeting CAR-T therapy.

关 键 词：Chimeric antigen receptor T cell therapy Diffuse large B-cell lymphoma IMMUNOTHERAPY PD-1 inhibitor Histone deacetylase inhibitor Case report 

分 类 号：R733.1[医药卫生—肿瘤]